Mergers & acquisitions
California-based Apexigen and two other companies are planning to move to the Nasdaq Stock Exchange following their mergers with SPACs.
Tokyo-based Eisai Inc. and Biogen announced modifications to their existing collaboration on developing the drug Aduhelm (aducanumab).
The drop in value has prompted MorphoSys to make drastic changes, such as discontinuing its U.S. operations and abandoning several pipeline projects.
Gilead Sciences is letting go of 114 employees following an underwhelming response to the results reaped so far from its $21 billion acquisition of Immunomedics in 2020.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
China has become a leader in biotech in the last five years, especially in CAR-T therapies. Companies like Johnson & Johnson are on the prowl to acquire Chinese companies to form collaborations.
The European Commission has provided an update that it remains unconvinced by the merger, which spells bad news for Illumina.
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
Shares of Adagene Inc. are up more than 10% in premarket trading after the company announced a monoclonal and bispecific antibody collaboration with Sanofi valued at up to $2.5 billion.
AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at up to $1 billion.
PRESS RELEASES